Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 983-990

  De Moura, Juliana ^a   Kavalec, Flávia Ludimila ^a   Doghman, Mabrouka ^b   Rosati, Roberto ^c   Custodio, Gislaine ^a   Lalli, Enzo ^b   Cavallari, Glaci Moura D ^a   Maria, Jesus Santa ^a   Figueiredo, Bonald C ^a,c  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c INSTITUTO DE PESQUISA PELÉ PEQUENO PRÍNCIPE   (Brazil)

Author keywords

Apoptosis; Cell proliferation; Li Fraumeni syndrome; TP53Arg72Pro polymorphism

Indexed keywords

CAPECITABINE; DNA; ETOPOSIDE; OXALIPLATIN; PROTEIN P21; PROTEIN P53; TAMOXIFEN; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TP53 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER DIAGNOSIS; CANCER FAMILY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DEATH; COLON ADENOCARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DNA ISOLATION; DYSPLASTIC NEVUS; FAMILIAL CANCER; FEMALE; FIBROBLAST; GENE DISRUPTION; GENE SEQUENCE; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; INTESTINE CANCER; INTRADUCTAL CARCINOMA; INTRON; LEUKEMIA; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDICAL DOCUMENTATION; MELANOMA; MENINGIOMA; MUCINOUS CARCINOMA; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; OVARY ADENOCARCINOMA; PANCREAS CANCER; PARAAORTIC LYMPH NODE; PATERNITY; PEDIGREE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETREATMENT; SALPINGOOOPHORECTOMY; SECOND CANCER; SEGMENTAL MASTECTOMY; SEQUENCE ANALYSIS; SKIN BIOPSY; STOP CODON; SURVIVAL TIME; APOPTOSIS; CASE REPORT; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; RADIATION EXPOSURE;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CODON, NONSENSE; CODON, TERMINATOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; ETOPOSIDE; FEMALE; FIBROBLASTS; GENOTYPE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; LI-FRAUMENI SYNDROME; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77749287000     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000578     Document Type: Article

References (50)

1. Li FP, Fraumeni, JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA and Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362, 1988.
2. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990.
3. Varley JM: Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21: 313-320, 2003.
4. Zambetti GP and Levine AJ: A comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-865, 1993.
5. Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412, 2008.
6. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
7. Soussi T, Dehouche K and Béroud C: P53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15: 105-113, 2000.
8. Soussi T and Béroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1: 233-240, 2001.
9. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ and Varley JM: Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17: 1061-1068, 1998.
10. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P and Eeles RA: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63: 6643-6650, 2003.
11. Sakamuro D, Sabbatini P, White E and Prendergast GC: The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15: 887-898, 1997.
12. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J and Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961-963, 1987.
13. Storey A, Thomas M, Kalita A, et al: Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229-234, 1998.
14. Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092-1100, 1999.
15. Lin HY, Huang CH, Wu WJ, Chang LC and Lung FW: TP53 codon 72 gene polymorphism paradox in associated with various carcinoma incidences, invasiveness and chemotherapy responses. Int J Biomed Sci 4: 248-254, 2008.
16. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
17. Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38: 1133-1141, 2006.
18. Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199, 2004.
19. Siddique M and Sabapathy K: Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500, 2006.
20. Knudson AG: Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162, 2001.
21. Vahakangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP and Harris CC: Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339: 576-580, 1992.
22. Willis A, Jung EJ, Wakefield T and Chen X: Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23: 2330-2338, 2004.
23. Sousa H, Santos AM, Pinto D and Medeiros R: Is the p53 codon 72 polymorphism a key biomarker forcervical cancer development? A meta-analysis review within European populations. Int J Mol Med 20: 731-741, 2007.
24. Akkiprik M, Sonmez O, Gulluoglu BM, et al: Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Oncol Res (In press).
25. Aoki MN, Da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH and Watanabe MA: CCR5 and p53 codon 72 gene polymorphisms: Implications in breast cancer development. Int J Mol Med 23: 429-435, 2009.
26. Brooks LA, Tidy JA, Gusterson B, et al: Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60: 6875-6877, 2000.
27. Marin MC, Jost CA, Brooks LA, et al: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47-54, 2000.
28. Tada M, Furuuchi K, Kaneda M, et al: Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 22: 515-517, 2001.
29. Furihata M, Takeuchi T, Matsumoto M, et al: p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 8: 1192-1195, 2002.
30. McGregor JM, Harwood CA, Brooks L, et al: Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 119: 84-90, 2002.
31. Papadakis ED, Soulitzis N and Spandidos DA: Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87: 1013-1018, 2002.
32. Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ and De Pancorbo MM: Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 193: 199-205, 2003.
33. Bonafé M, Ceccarelli C, Farabegoli F, et al: Retention of the p53 codon 72 arginine allele is associated with a reduction of diseasefree and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9: 4860-4864, 2003.
34. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F and Roessner A: Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6: 529-535, 2004.
35. Scheckenbach K, Lieven O, Götte K, Bockmühl U, Zotz R, Bier H and Balz V: p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev 13: 1805-1809, 2004.
36. Nelson HH, Wilkojmen M, Marsit CJ and Kelsey KT: TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 26: 1770-1773, 2005.
37. Kyndi M, Alsner J, Hansen LL, Sørensen FB and Overgaard J: LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol 45: 602-609, 2006.
38. Wegman PP, Marcus JN, Malakkaran BP and Wingren S: Biological significance of allele specific loss of the p53 gene in breast carcinomas. Breast Cancer Res Treat (In press).
39. Phang BH and Sabapathy K: The codon 72 polymorphismspecific effects of human p53 are absent in mouse cells: implications on generation of mouse models. Oncogene 26: 2964-2974, 2007.
40. Sullivan A, Syed N, Gasco M, et al: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vitro. Oncogene 23: 3328-3337, 2004.
41. Bergamaschi D, Gasco M, Hiller L, et al: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387-402, 2003.
42. Lynch CJ and Milner J: Loss of one p53 allele results in fourfold reduction of p53 mRNA and protein: a basis for p53 haploinsufficiency. Oncogene 25: 3463-3470, 2006.
43. Ponder B: Cancer. Gene losses in human tumors. Nature 335: 400-402, 1988.
44. Burt EC, James LA, Greaves MJ, Birch JM, Boyle JM and Varley JM: Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts. Br J Cancer 83: 467-472, 2000.
45. Boyle JM, Spreadborough AR, Greaves MJ, Birch JM, Varley JM and Scott D: Delayed chromosome changes in gamma-irradiated normal and Li-Fraumeni fibroblasts. Radiat Res 157: 158-165, 2002.
46. 1 arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without TP53 mutations. Br J Cancer 85: 293-296, 2001.
47. Lustbader ED, Williams WR, Bondy ML, Strom S and Strong LC: Segregation analysis of cancer in families of childhood softtissue-sarcoma patients. Am J Hum Genet 51: 344-356, 1992.
48. Bougeard G, Baert-Desurmont S, Tournier I, et al: Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531-533, 2006.
49. Ellis NA, Huo D, Yildiz O, et al: MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 112: 741-749, 2008.
50. Nutting C, Camplejohn RS, GiIchrist R, et al: A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 12: 300-304, 2000.